Get the Stockscreener App
0.5818
16.56%
0.0871
Entero Therapeutics Inc stock is traded at $0.5818, with a volume of 8.54M.
It is up +16.56% in the last 24 hours and up +1.16% over the past month.
Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address significant unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.
See More
Previous Close:
$0.4947
Open:
$0.7286
24h Volume:
8.54M
Relative Volume:
31.82
Market Cap:
$3.04M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+19.88%
1M Performance:
+1.16%
6M Performance:
+37.29%
1Y Performance:
+0.00%
1-Day Range:
$0.55
$0.8989
1-Week Range:
$0.465
$0.8989
52-Week Range:
$0.185
$3.00
Entero Therapeutics Inc Stock (ENTO) Company Profile
Name
Entero Therapeutics Inc
Sector
Industry
Phone
561-589-7020
Address
777 YAMATO ROAD, BOCA RATON
Compare ENTO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENTO
Entero Therapeutics Inc
|
0.587 | 3.04M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
490.05 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
688.27 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
632.13 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.03 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
112.82 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Entero Therapeutics Inc Stock (ENTO) Latest News
Entero Therapeutics Appoints Richard Paolone as CEO - citybiz
AzurRx BioPharma Receives Approximately $550,000 for its 2020 CIR (French Research Tax Credit) - Marketscreener.com
Entero Therapeutics names Richard Paolone interim CEO - MSN
Entero Therapeutics Appoints Richard Paolone as Interim CEO - TipRanks
Entero Therapeutics names Richard Paolone interim CEO By Investing.com - Investing.com South Africa
Entero Therapeutics Names Richard Paolone Interim CEO - MarketWatch
Entero Therapeutics Names Richard Paolone Interim CEO -February 14, 2025 at 04:25 pm EST - Marketscreener.com
Strategic Leadership Shift: M&A Expert Takes Helm at Entero TherapeuticsKey Details Revealed - StockTitan
Entero Therapeutics, Inc. announced that it has received $2 million in funding from 1396974 B.C. Ltd - Marketscreener.com
Entero Therapeutics Inc (ENTO) Shares Soar Above 1-Year High - The News Heater
Entero Therapeutics Appoints Three New Board Members - citybiz
Entero Therapeutics Gets $2 Million Revolving Loan, Appoints 3 New Board Members - Marketscreener.com
Entero Therapeutics Secures $2 Million Revolving Loan; Appoints Three New Board Members - The Manila Times
Entero Therapeutics Secures $2 Million Loan and Appoints New Board Members - Nasdaq
Entero Therapeutics, Inc. Announces Board Changes -February 07, 2025 at 03:22 pm EST - Marketscreener.com
Major Board Shakeup at Entero Therapeutics as $2M Financing Deal Forces Director Changes - StockTitan
Entero Therapeutics Announces Board of Directors Restructuring - TipRanks
AzurRx BioPharma Announces Results of Phase IIa Trial of MS1819-SD in Exocrine Pancreatic Insufficiency - Marketscreener.com
Entero Therapeutics faces Nasdaq delisting over meeting lapse By Investing.com - Investing.com Australia
Entero Therapeutics faces Nasdaq delisting over meeting lapse - Investing.com
Entero therapeutics CFO sells $465 in stock - Investing.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SUM, STAF, ALVR, ENTO on Behalf of Shareholders - The Malaysian Reserve
$HAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues to Investigate the Mergers of SUM, ENTO, ALVR and STAF - GlobeNewswire Inc.
ENTO (Entero Therapeutics) Price-to-Operating-Cash-Flow : (As of Dec. 04, 2024) - GuruFocus.com
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
First Wave BioPharma, Inc. announced that it expects to receive $4 million in funding - Marketscreener.com
Deal Watch: Sarepta Targets RNAi In Broad Collaboration With Arrowhead - Citeline News & Insights
Entero Therapeutics faces financial obligations acceleration By Investing.com - Investing.com Nigeria
Entero Therapeutics faces financial obligations acceleration - Investing.com India
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates STAF, ATSG, ENTO, AVTE on Behalf of Shareholders - Marketscreener.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CDE, ALVR, PULM, ENTO on Behalf of Shareholders - The Malaysian Reserve
Finansavisen - Finansavisen
Celiac Disease Pipeline Grows as 25+ Key Pharma Companies Join the Fight for Innovative Treatments | DelveInsight - PR Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates - GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders - AccessWire
ENTERO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Entero Therapeutics, Inc.ENTO - Marketscreener.com
Entero Therapeutics CEO James Sapirstein to Moderate the 2024 BioFlorida Annual Innovation Conference CEO Forum - The Manila Times
Entero Therapeutics announces proposed reverse merger with Journey Therapeutics - TipRanks
Entero finds lifeline in reverse merger with nano-immunoconjugate firm Journey - FirstWord Pharma
Ademi LLP Investigates Whether Entero Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders - Business Wire
Shareholder Alert: Ademi LLP Investigates Whether Entero Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders - The Bakersfield Californian
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AE, LBRDA, PULM, ENTO on Behalf of Shareholders - The Malaysian Reserve
ENTO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Entero Therapeutics, Inc. Is Fair to Shareholders - Business Wire
Entero Therapeutics Inc Stock (ENTO) Financials Data
There is no financial data for Entero Therapeutics Inc (ENTO). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Entero Therapeutics Inc Stock (ENTO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Romano Sarah | Chief Financial Officer |
Oct 09 '24 |
Sale |
0.45 |
476 |
212 |
18,014 |
| Romano Sarah | Chief Financial Officer |
Jul 02 '24 |
Sale |
1.07 |
621 |
664 |
18,490 |
| SAPIRSTEIN JAMES | Chairman and CEO |
Jul 02 '24 |
Sale |
1.07 |
1,289 |
1,379 |
35,816 |
| SAPIRSTEIN JAMES | Chairman and CEO |
Apr 01 '24 |
Sale |
4.23 |
174 |
736 |
37,105 |
| Romano Sarah | Chief Financial Officer |
Apr 01 '24 |
Sale |
4.23 |
75 |
317 |
19,111 |
| SAPIRSTEIN JAMES | Chairman and CEO |
Mar 15 '24 |
Sale |
4.96 |
1,887 |
9,360 |
37,279 |
| Romano Sarah | Chief Financial Officer |
Mar 15 '24 |
Sale |
4.96 |
1,120 |
5,555 |
19,186 |
4.34%
1.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):